Access cutting-edge respiratory syncytial virus (rsv) treatment through this clinical trial at a research site in Wilmington. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Wilmington location
Preparing your pre-screening questions…
Access respiratory syncytial virus (rsv) specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related respiratory syncytial virus (rsv) treatment provided free
Check if you qualify for this respiratory syncytial virus (rsv) clinical trial in Wilmington, NC
No-Cost Study Care
Local to Wilmington
Convenient for NC residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
The research question is: What is the risk of adverse pregnancy outcomes, including preterm birth, hypertensive disorders, and other maternal and neonatal/infant outcomes, following exposure to RSV vaccine between 32 weeks, 0 days and 36 weeks, 6 days of gestation in the CorEvitas Respiratory Syncytial Virus Vaccine Pregnancy Registry (RSV-PR)? The primary study objective is to estimate the risk of (1) preterm birth and (2) hypertensive disorders following exposure to RSV vaccine between 32 weeks, 0 days and 36 weeks, 6 days of gestation. The secondary study objective is to estimate the risk of other safety outcomes of interest following exposure to RSV vaccine between 32 weeks, 0 days and 36 weeks, 6 days of gestation, including: * Pregnancy-related outcomes: stillbirth, premature labor, premature rupture of membranes, preterm premature rupture of membranes, cesarean delivery, prolonged maternal duration of hospital stay * Maternal outcomes: thrombocytopenia, Guillain-Barré syndrome, other immune-mediated demyelinating conditions, polyneuropathies, atrial fibrillation, maternal death * Neonatal/infant outcomes: small for gestational age, large for gestational age, low birth weight, admission to a neonatal intensive care unit (NICU), NICU duration of stay, mechanical ventilation in neonatal period, neonatal death, postnatal growth at 1 year of age The exploratory study objective is to describe the most frequently reported maternal adverse events following exposure to RSV vaccine between 32 weeks, 0 days and 36 weeks, 6 days of gestation.
Sponsor: CorEvitas
Yes, this clinical trial (NCT06521944) has an active research site in Wilmington, NC that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for respiratory syncytial virus (rsv) treatment options in Wilmington, NC, this clinical trial (NCT06521944) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Wilmington research site is actively enrolling participants for this clinical trial. You'll receive care from experienced respiratory syncytial virus (rsv) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all respiratory syncytial virus (rsv) clinical trials near you to find additional studies recruiting in your area.
See all rheumatoid arthritis clinical trials recruiting in Wilmington — not just this study.
Browse Rheumatoid Arthritis Trials in Wilmington →